• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

    6/24/24 3:32:55 AM ET
    $EPAC
    $ITI
    $OMIC
    $STOK
    Industrial Machinery/Components
    Technology
    Telecommunications Equipment
    Telecommunications
    Get the next $EPAC alert in real time by email

    With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to report quarterly earnings at 47 cents per share on revenue of $153.20 million after the closing bell. Enerpac Tool Group shares gained 1.9% to $39.22 in after-hours trading.
    • Singular Genomics Systems, Inc. (NASDAQ:OMIC) reported a 1-for-30 reverse stock split. Singular Genomics shares fell 9.3% to $0.3180 in the after-hours trading session.
    • Analysts are expecting Beyond Air, Inc. (NASDAQ:XAIR) to post a quarterly loss at $0.48 per share on revenue of $747.20 thousand. The company will release earnings after the markets close. Beyond Air shares gained 8.1% to $1.34 in after-hours trading.

    Check out our premarket coverage here

    • Iteris, Inc. (NASDAQ:ITI) filed for a $150 million mixed securities shelf offering. Iteris shares fell 1.2% to $4.0201 in the after-hours trading session.
    • Stoke Therapeutics, Inc. (NASDAQ:STOK) said its Chief Operating Officer Huw Nash will step down, but will continue as Chief Business Officer, effective June 18. Stoke Therapeutics shares fell 3.6% to close at $14.23 on Friday.

    Check This Out: $2M Bet On Exxon Mobil? Check Out These 3 Stocks Insiders Are Buying

    Get the next $EPAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPAC
    $ITI
    $OMIC
    $STOK

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Enerpac Tool Group Corp.
    $EPAC
    1/16/2026Mkt Perform
    William Blair
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Enerpac Tool Group Corp.
    $EPAC
    9/5/2025$48.00Buy
    Roth Capital
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Stoke Therapeutics Inc.
    $STOK
    12/20/2024$24.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    10/14/2024$18.00Outperform
    Leerink Partners
    More analyst ratings

    $EPAC
    $ITI
    $OMIC
    $STOK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    2/17/26 4:58:35 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.

    SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    2/17/26 4:13:34 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    2/17/26 6:47:48 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

    –Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives– –ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Do

    2/11/26 7:30:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Sto

    2/4/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

    New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts Lease is One of the Largest in Greater Boston Life Sciences Over the Past Year WALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (NASDAQ:STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company's current lease in Bedford, Massachusetts ends in late 2026.

    1/27/26 2:05:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Enerpac Tool Group

    William Blair initiated coverage of Enerpac Tool Group with a rating of Mkt Perform

    1/16/26 8:41:55 AM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Healy Colleen was granted 3,134 shares, increasing direct ownership by 33% to 12,632 units (SEC Form 4)

    4 - ENERPAC TOOL GROUP CORP (0000006955) (Issuer)

    2/9/26 4:39:36 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Minella Lynn C

    4 - ENERPAC TOOL GROUP CORP (0000006955) (Issuer)

    2/9/26 4:36:00 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Holder Richard D

    4 - ENERPAC TOOL GROUP CORP (0000006955) (Issuer)

    2/9/26 4:34:30 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    $EPAC
    $ITI
    $OMIC
    $STOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Leadership Updates

    Live Leadership Updates

    View All

    STRATTEC SECURITY CORPORATION Appoints Matthew Pauli as Chief Financial Officer Effective November 13, 2024

    Dennis Bowe to continue in advisory role to support transition STRATTEC SECURITY CORPORATION (NASDAQ:STRT) ("STRATTEC" or "Company"), a leading provider of smart vehicle power access, security & authorization solutions for the global automotive industry, today announced the Board of Directors of STRATTEC has appointed Matthew Pauli as Senior Vice President, Chief Financial Officer effective November 13, 2024. He will succeed Dennis Bowe, who will be continuing with the Company in an advisory role to aid in the transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111337953/en/The Board of Directors of STRATTEC has appo

    11/11/24 4:15:00 PM ET
    $EPAC
    $STRT
    Industrial Machinery/Components
    Technology
    Auto Parts:O.E.M.
    Consumer Discretionary

    Enerpac Tool Group Announces Darren Kozik Appointed EVP & Chief Financial Officer

    MILWAUKEE, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Enerpac Tool Group Corp. (NYSE:EPAC) ("Enerpac" or "the Company") announced today that Darren M. Kozik is joining the Company as Executive Vice President and Chief Financial Officer effective October 28, 2024. He will report to Paul Sternlieb, President & CEO, and serve as a member of the Company's executive leadership team. Mr. Kozik will provide leadership over all aspects of the Company's finance and IT functions globally. Mr. Kozik joins Enerpac Tool Group from ManpowerGroup, a leading global workforce solutions company. With 25 years of finance experience, he most recently held the position of SVP, Global Corporate Finance, where he led th

    10/15/24 4:00:00 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

    – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

    9/4/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/22/24 7:55:51 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPAC
    $ITI
    $OMIC
    $STOK
    Financials

    Live finance-specific insights

    View All

    Enerpac Tool Group Reports First Quarter Fiscal 2026 Results

    First Quarter of Fiscal 2026 Highlights* Net sales were $144 million, a 1% decrease compared to the prior year.Operating margin and adjusted operating margin was 19.8%.Net earnings were $19.1 million, or $0.36 per diluted share.Adjusted EBITDA was $32.4 million and adjusted EBITDA margin was 22.4%.Operating cash flow was $16 million, up from $9 million in the prior year.Returned approximately $15 million to shareholders through share repurchases. *This press release contains financial measures in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") in addition to non-GAAP financial measures. Reconciliations of the non-GAAP financial measures to the comparable GAAP measure

    12/17/25 4:30:00 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    Enerpac Tool Group Schedules First Quarter Fiscal 2026 Earnings Release and Conference Call

    MILWAUKEE, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Enerpac Tool Group Corp. (NYSE:EPAC) announced today that it will release its first quarter fiscal 2026 earnings after the market closes on Wednesday, December 17, 2025. Management will conduct a conference call to discuss the results on Thursday, December 18, 2025, beginning at 8:30 a.m. ET / 7:30 a.m. CT. A real-time webcast of the conference call can be accessed via the Investors section of the Company's website. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call for 90 days. About Enerpac Tool Group Enerpac Tool Group Corp. is a premier industrial tools, services, technology, a

    12/10/25 8:00:00 AM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    – Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 – – Webcast and conference call for analysts and investors at 4:30PM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a fi

    11/4/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care